Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing

With several recent FDA approvals and a strong drug pipeline, the gene therapy market is coming of age and providing new hope for patients. As demand for these new therapies increases, a robust and scalable manufacturing process is critical. In this webinar, we will present an end user case study which illustrates the challenges and solutions to scale both the upstream and downstream process steps required to manufacture adenoviruses.

 

Participants will learn how to:

 

• Accelerate time to market for adenovirus manufacturing

• Design the process for scalability

• Reduce downstream processing time from 3 - 4 days to 1 day

Speakers

clive glover

Clive Glover, PhD

 

Senior Marketing Manager, Cell & Gene Therapy

Pall Biotech

Biography

Rachel Legmann

Rachel Legmann, PhD

 

Senior Manager, Process Development Services

Pall Biotech

Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing

Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing

2018-11-07T16:00:00.000Z
더 Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
May 2021
Overcome Exosome Production Challenges

Biotech | Pall Corporation 웨비나 시리즈

Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.

David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.

Participants will be able to:

 

  • Compare the performance of the iCELLis Nano bioreactor to traditional flasks for exosome production from adherent cell culture
  • Understand how an integrated end to end platform delivers highly   purified and consistently-sized exosomes
  • Discover an innovative cGMP scalable manufacturing platform for   exosomes
시청